How much does skin barrier count for allergic dermatitis improvement?

Detalhes bibliográficos
Autor(a) principal: Martins, Luís
Data de Publicação: 2018
Outros Autores: Fialho, Luísa, Caldeira, Joana, Sliva, Nídia, Antunes, Célia, Costa, Ana, Goicoa, Ana, Bento, Ofélia
Tipo de documento: Artigo de conferência
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10174/23510
https://doi.org/10.13140/RG.2.2.20481.56163
Resumo: Background Allergic dermatitis is a genetic-based skin condition affecting an increasing number of dogs. A more efficient treatment approach is often multimodal, including a special focus on skin barrier condition, from which many pruritic triggers depend as well as common complications. Aim: To evaluate the specific role of skin barrier-directed reestablishing treatment in allergic dermatitis clinical improvement. Method Five dogs with allergic dermatitis were selected from an allergy outpatient consultation. Owners’ informed consent was obtained upon approval by an ethics committee. Patients were subjected to clinical work up including Canine Atopic Dermatitis Extent and Severity Index 4 (CADESI-4) and specific diagnosis for atopy and/or food allergy, including intradermal testing (IDT). Skin biopsies were performed from a non-infected inflamed and adjacent non-affected area, and conserved in 4% buffered formaldehyde. Follow up lasted for 2-3 months, applying avoidance measures directed to the implicated allergen sources and treating with a phytosphingosine-containing shampoo/lotion, according to the manufacturer’s directions. Reassessment was done each 10-15 days with CADESI-4 and further IDT and skin biopsies performed at the end. Skin samples were histologically processed including staining for mastocytes and collagen fibers. Thickness of the non-keratinized epidermal layer and stratum corneum as well this lamina organization (scored 1-5), mast cell density and integrity, and collagen density in the dermal layer were assessed. Normal (N) and lesion (L) data, before and after treatment, were compared. Results Three patients showed evident clinical improvement, 1 moderately and 1 not (10-19, 3 and 1 respectively decrease in CADESI-4). IDT results did not differ. Non-keratinized epidermal layer and stratum corneum thickness ranged respectively 12/4 (N) to 330/300 μm (L) before treatment and 10/4 (N) to 120/120 μm (L) after treatment. Lamina cornea organization tended to increase with treatment, with no clear change in collagen fibers. Mast cell density improved in the recovered patients with 15.2% drop and integrity increased 22.8%. Conclusion Skin barrier-directed reestablishing treatment in allergic dermatitis allows for effective and significant clinical improvement, even as single choice treatment, and therefore should be considered as a non-side-effect treatment, especially when a curative immunological approach is not possible or ineffective.
id RCAP_4570b4456758895d02281b67b8fdb8ac
oai_identifier_str oai:dspace.uevora.pt:10174/23510
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling How much does skin barrier count for allergic dermatitis improvement?AllergySkinDogDermatitisBackground Allergic dermatitis is a genetic-based skin condition affecting an increasing number of dogs. A more efficient treatment approach is often multimodal, including a special focus on skin barrier condition, from which many pruritic triggers depend as well as common complications. Aim: To evaluate the specific role of skin barrier-directed reestablishing treatment in allergic dermatitis clinical improvement. Method Five dogs with allergic dermatitis were selected from an allergy outpatient consultation. Owners’ informed consent was obtained upon approval by an ethics committee. Patients were subjected to clinical work up including Canine Atopic Dermatitis Extent and Severity Index 4 (CADESI-4) and specific diagnosis for atopy and/or food allergy, including intradermal testing (IDT). Skin biopsies were performed from a non-infected inflamed and adjacent non-affected area, and conserved in 4% buffered formaldehyde. Follow up lasted for 2-3 months, applying avoidance measures directed to the implicated allergen sources and treating with a phytosphingosine-containing shampoo/lotion, according to the manufacturer’s directions. Reassessment was done each 10-15 days with CADESI-4 and further IDT and skin biopsies performed at the end. Skin samples were histologically processed including staining for mastocytes and collagen fibers. Thickness of the non-keratinized epidermal layer and stratum corneum as well this lamina organization (scored 1-5), mast cell density and integrity, and collagen density in the dermal layer were assessed. Normal (N) and lesion (L) data, before and after treatment, were compared. Results Three patients showed evident clinical improvement, 1 moderately and 1 not (10-19, 3 and 1 respectively decrease in CADESI-4). IDT results did not differ. Non-keratinized epidermal layer and stratum corneum thickness ranged respectively 12/4 (N) to 330/300 μm (L) before treatment and 10/4 (N) to 120/120 μm (L) after treatment. Lamina cornea organization tended to increase with treatment, with no clear change in collagen fibers. Mast cell density improved in the recovered patients with 15.2% drop and integrity increased 22.8%. Conclusion Skin barrier-directed reestablishing treatment in allergic dermatitis allows for effective and significant clinical improvement, even as single choice treatment, and therefore should be considered as a non-side-effect treatment, especially when a curative immunological approach is not possible or ineffective.CEVA Animal HealthEuropean Academy of Allergy and Clinical Immunology2018-10-04T11:12:06Z2018-10-042018-05-26T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjecthttp://hdl.handle.net/10174/23510http://hdl.handle.net/10174/23510https://doi.org/10.13140/RG.2.2.20481.56163engMartins LM, Fialho LR, Caldeira J, Silva N, Antunes C, Costa AR, Goicoa A, Bento O. How much does skin barrier count for allergic dermatitis improvement? P1877. EAACI 2018. May 26-30.naonaosimlmlm@uevora.ptlfialho@uevora.ptjoanaec@uevora.ptnidia.silva@ceva.comcmma@uevora.ptacrc@uevora.ptana.goicoa@usc.esofelia@uevora.pt382Martins, LuísFialho, LuísaCaldeira, JoanaSliva, NídiaAntunes, CéliaCosta, AnaGoicoa, AnaBento, Oféliainfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-01-03T19:15:16Zoai:dspace.uevora.pt:10174/23510Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T01:14:07.102294Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv How much does skin barrier count for allergic dermatitis improvement?
title How much does skin barrier count for allergic dermatitis improvement?
spellingShingle How much does skin barrier count for allergic dermatitis improvement?
Martins, Luís
Allergy
Skin
Dog
Dermatitis
title_short How much does skin barrier count for allergic dermatitis improvement?
title_full How much does skin barrier count for allergic dermatitis improvement?
title_fullStr How much does skin barrier count for allergic dermatitis improvement?
title_full_unstemmed How much does skin barrier count for allergic dermatitis improvement?
title_sort How much does skin barrier count for allergic dermatitis improvement?
author Martins, Luís
author_facet Martins, Luís
Fialho, Luísa
Caldeira, Joana
Sliva, Nídia
Antunes, Célia
Costa, Ana
Goicoa, Ana
Bento, Ofélia
author_role author
author2 Fialho, Luísa
Caldeira, Joana
Sliva, Nídia
Antunes, Célia
Costa, Ana
Goicoa, Ana
Bento, Ofélia
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Martins, Luís
Fialho, Luísa
Caldeira, Joana
Sliva, Nídia
Antunes, Célia
Costa, Ana
Goicoa, Ana
Bento, Ofélia
dc.subject.por.fl_str_mv Allergy
Skin
Dog
Dermatitis
topic Allergy
Skin
Dog
Dermatitis
description Background Allergic dermatitis is a genetic-based skin condition affecting an increasing number of dogs. A more efficient treatment approach is often multimodal, including a special focus on skin barrier condition, from which many pruritic triggers depend as well as common complications. Aim: To evaluate the specific role of skin barrier-directed reestablishing treatment in allergic dermatitis clinical improvement. Method Five dogs with allergic dermatitis were selected from an allergy outpatient consultation. Owners’ informed consent was obtained upon approval by an ethics committee. Patients were subjected to clinical work up including Canine Atopic Dermatitis Extent and Severity Index 4 (CADESI-4) and specific diagnosis for atopy and/or food allergy, including intradermal testing (IDT). Skin biopsies were performed from a non-infected inflamed and adjacent non-affected area, and conserved in 4% buffered formaldehyde. Follow up lasted for 2-3 months, applying avoidance measures directed to the implicated allergen sources and treating with a phytosphingosine-containing shampoo/lotion, according to the manufacturer’s directions. Reassessment was done each 10-15 days with CADESI-4 and further IDT and skin biopsies performed at the end. Skin samples were histologically processed including staining for mastocytes and collagen fibers. Thickness of the non-keratinized epidermal layer and stratum corneum as well this lamina organization (scored 1-5), mast cell density and integrity, and collagen density in the dermal layer were assessed. Normal (N) and lesion (L) data, before and after treatment, were compared. Results Three patients showed evident clinical improvement, 1 moderately and 1 not (10-19, 3 and 1 respectively decrease in CADESI-4). IDT results did not differ. Non-keratinized epidermal layer and stratum corneum thickness ranged respectively 12/4 (N) to 330/300 μm (L) before treatment and 10/4 (N) to 120/120 μm (L) after treatment. Lamina cornea organization tended to increase with treatment, with no clear change in collagen fibers. Mast cell density improved in the recovered patients with 15.2% drop and integrity increased 22.8%. Conclusion Skin barrier-directed reestablishing treatment in allergic dermatitis allows for effective and significant clinical improvement, even as single choice treatment, and therefore should be considered as a non-side-effect treatment, especially when a curative immunological approach is not possible or ineffective.
publishDate 2018
dc.date.none.fl_str_mv 2018-10-04T11:12:06Z
2018-10-04
2018-05-26T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/conferenceObject
format conferenceObject
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10174/23510
http://hdl.handle.net/10174/23510
https://doi.org/10.13140/RG.2.2.20481.56163
url http://hdl.handle.net/10174/23510
https://doi.org/10.13140/RG.2.2.20481.56163
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Martins LM, Fialho LR, Caldeira J, Silva N, Antunes C, Costa AR, Goicoa A, Bento O. How much does skin barrier count for allergic dermatitis improvement? P1877. EAACI 2018. May 26-30.
nao
nao
sim
lmlm@uevora.pt
lfialho@uevora.pt
joanaec@uevora.pt
nidia.silva@ceva.com
cmma@uevora.pt
acrc@uevora.pt
ana.goicoa@usc.es
ofelia@uevora.pt
382
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv European Academy of Allergy and Clinical Immunology
publisher.none.fl_str_mv European Academy of Allergy and Clinical Immunology
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136622963326976